Moderna says it was willing to licence the tech but now wants to be repaid by rivals for vaccine revenue generated since then.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The figure was enough to push the insurance giant to a loss in Q1, despite its revenue beating expectations.
The company announced positive results in an early-stage trial of the individualized cancer vaccine it developed with Merck.
The filings signal the growing use cases for AI in healthcare settings, but also the risks that may accompany using AI in clinical care.
A GLP-1 medication from French drugmaker Sanofi — similar to Ozempic — was found to slow Parkinson’s in a small mid-stage trial.
Demand for senior living facilities is inching back toward pre-pandemic levels. But how that demand will be met is still an open question.
Novo Nordisk has announced a new drug in its pipeline performed much better than Wegovy in helping participants to lose weight.
The company’s stock ran higher after the company buoyed investors’ hopes that its technology will boost a lineup of new popular drugs.
The investigation is targeting so-called middlemen that broker deals between hospitals and pharmaceutical companies.
The growing sector scored its second-highest month ever for total money-raising.
The company, now one of Europe’s biggest, is trying to keep supply up with still-astronomical demand.
After a solid 2023, shares of WW International just experienced their worst month ever, falling nearly 60% amid signs of waning demand.
Many of the medicines are the most popular in the sector, including popular weight loss drugs Ozempic and Mounjaro.
The US government designed a program to incentivize the development of treatments for rare tropical diseases. Big Pharma had other plans.
Pfizer’s stock slumped its lowest level in more than 10 years. The world’s moved on from the pandemic, and nobody loves you when you’re down.
Following merger discussions two weeks ago, Humana and Cigna are walking away from what would’ve been the largest deal of the year.